Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$75,732.00+0.11%ETH$2,395.37-0.09%GOLD$4,312.70-1.70%OIL$101.96-0.46%
Smart Investors Daily
ZN

NASDAQ · ZNTL

Zentalis Pharmaceuticals, Inc.

Healthcare · Biotechnology

$3.13

Down-$0.03 (-0.96%)

Updated Sep 16, 2026, 10:51 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
104.4M
P/E ratio
-0.64
Dividend yield
0.00%
52-week range
$1.21 – $6.95
Volume
1.4M
Avg. volume
673.52K

Price performance

ZNTL price history

1M range · 20 trading sessions · Daily adjusted prices

ZNTL closed at $3.13 after 20 trading sessions, down 14.95% for the selected period.

Last close
$3.13
Period change
-14.95%
Period low
$3.13
Period high
$4.11
Daily close
View OHLC price history
ZNTL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$3.51$3.51$3.12$3.131.4M
Sep 14, 2026$3.47$3.57$3.44$3.50750.36K
Sep 11, 2026$3.63$3.67$3.465$3.51787.86K
Sep 10, 2026$3.74$3.765$3.555$3.59864.21K
Sep 9, 2026$3.99$4.039$3.79$3.80782.55K
Sep 8, 2026$4.00$4.10$3.885$4.03519.17K
Sep 4, 2026$4.05$4.1851$3.92$3.991M
Sep 3, 2026$3.80$4.12$3.73$4.111.37M
Sep 2, 2026$3.68$3.88$3.68$3.77897.8K
Sep 1, 2026$3.68$3.74$3.55$3.71863.86K
Aug 31, 2026$3.79$3.79$3.67$3.76471.81K
Aug 28, 2026$3.88$3.89$3.72$3.80695.42K
Aug 27, 2026$3.87$3.92$3.82$3.88430.1K
Aug 26, 2026$3.87$3.93$3.83$3.89576.21K
Aug 25, 2026$3.78$3.89$3.78$3.88799.15K
Aug 24, 2026$3.84$3.96$3.75$3.76988.68K
Aug 21, 2026$3.95$3.95$3.815$3.825741.8K
Aug 20, 2026$4.015$4.04$3.78$3.841.57M
Aug 19, 2026$3.76$3.86$3.66$3.821.78M
Aug 18, 2026$3.75$3.86$3.58$3.681.2M

Latest ZNTL news

The latest Smart Investors Daily articles mentioning ZNTL.

Stock researchCompany · Overview

ZNTL research

Overview

Company profile and research snapshot.

Company profile

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
ZNTL recent ratings
DateFirmRatingTarget
Jul 23, 2026Rodman & RenshawBuy—
Jul 17, 2026MizuhoOutperform—
Apr 10, 2026GuggenheimBuy—
Mar 27, 2026GuggenheimBuy—
Nov 12, 2025Morgan StanleyEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston, MA. Fireside discussion, September 8, 2026, 4:30p

Yahoo · Sep 1, 2026

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By